Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Edgar G. Engleman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2096-9279; OpenAlex author ID A5034001543; NIH RePORTER profile ID 1862821. Sources: ClinicalTrials.gov.

Their work

Papers
5 (first author 0, last author 1)
Trials
1 (principal investigator on 1)
Grants
4
Labs led
1
Collaborators
31
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: 1 grant · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper, 1 grant · 2024: none · 2025: 1 grant · 2026: 1 grant

Papers 5

  1. Conditional Knockout of Hypoxia-Inducible Factor 1-Alpha in Tumor-Infiltrating Neutrophils Protects against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms24010753↗
  2. Antitumor effects of iPSC-based cancer vaccine in pancreatic cancer. Co-author DOI 10.1016/j.stemcr.2021.04.004↗
  3. Targeting Glycolysis in Macrophages Confers Protection Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms22126350↗
  4. The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and D… Co-author DOI 10.1097/mpa.0000000000001037↗
  5. An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-16-2212↗

Trials 1

  1. Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer Principal investigator NCT00547144↗

Grants 4

  1. Targeting Lymph Node Dependent Immune Tolerance in Cancer R01CA251174↗
  2. Administrative and Biostatistics Core P01CA244114↗
  3. Innate Immune Mechanisms Contributing to Cancer Growth in Obesity R01CA262361↗
  4. Biology and Immunology of Pancreatic Cancer Stem Cells in a Novel Mouse Model U01CA141468↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Garry Nolan · 1 shared grant, 2025 · strength 0.57
  2. Seung K Kim · 1 shared grant, 2025 · strength 0.57
  3. Steven E Artandi · 1 shared grant, 2025 · strength 0.57
  4. Mara H. Sherman · 1 shared grant, 2025 · strength 0.57
  5. Walter Gwang-Up Park · 1 shared grant, 2025 · strength 0.57
  6. Laura D Attardi · 1 shared grant, 2025 · strength 0.57
  7. Je Lin Sieow · 2 shared papers, 2021–2023 · strength 0.24
  8. Siew Cheng Wong · 2 shared papers, 2021–2023 · strength 0.24
  9. Hweixian Leong Penny · 2 shared papers, 2021–2023 · strength 0.24
  10. Aida Habtezion · 2 shared papers, 2018–2021 · strength 0.17
  11. Justin A. Kenkel · 2 shared papers, 2017–2021 · strength 0.16
  12. Joseph C. Wu · 1 shared paper, 2021 · strength 0.11
  13. Xiaoming Ouyang · 1 shared paper, 2021 · strength 0.11
  14. Nigel G. Kooreman · 1 shared paper, 2021 · strength 0.11
  15. Florent Ginhoux · 1 shared paper, 2021 · strength 0.09
  16. E. Scott Seeley · 1 shared paper, 2017 · strength 0.07
  17. William E. Fisher · 1 shared paper, 2018 · strength 0.06
  18. James L. Abbruzzese · 1 shared paper, 2018 · strength 0.06
  19. Alvin C. Powers · 1 shared paper, 2018 · strength 0.06
  20. Murray Korc · 1 shared paper, 2018 · strength 0.06
  21. Carl A.K. Borrebaeck · 1 shared paper, 2018 · strength 0.06
  22. Dana K. Andersen · 1 shared paper, 2018 · strength 0.06
  23. Zobeida Cruz‐Monserrate · 1 shared paper, 2018 · strength 0.06
  24. Stephen Jacob Pandol · 1 shared paper, 2018 · strength 0.06
  25. Anil K. Rustgi · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.